Dr. Matthew Pianko, M.D.
Claim this profileUniversity of Michigan
Studies Multiple Myeloma
Studies Plasma Cell Neoplasm
4 reported clinical trials
10 drugs studied
Affiliated Hospitals
Clinical Trials Matthew Pianko, M.D. is currently running
Mezigdomide Combo vs. Pomalidomide Combo
for Multiple Myeloma
This trial is testing two drug combinations to find out which one is better and safer for patients with multiple myeloma that has come back or not responded to previous treatments. The drugs work together to kill cancer cells by stopping their growth, helping the immune system attack them, and making it harder for them to survive.
Recruiting2 awards Phase 3
Lenalidomide +/- Daratumumab
for Multiple Myeloma
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Step 3) to either continue or discontinue the assigned treatment. Patients are treated for up to 7 years from Step 2 reg and followed for up to 15 years.
Recruiting2 awards Phase 317 criteria
More about Matthew Pianko, M.D.
Clinical Trial Related2 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Matthew Pianko, M.D. has experience with
- Dexamethasone
- Bortezomib
- Lenalidomide
- Pomalidomide
- Daratumumab
- CC-92480
Breakdown of trials Matthew Pianko, M.D. has run
Multiple Myeloma
Plasma Cell Neoplasm
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew Pianko, M.D. specialize in?
Matthew Pianko, M.D. focuses on Multiple Myeloma and Plasma Cell Neoplasm. In particular, much of their work with Multiple Myeloma has involved treating patients, or patients who are undergoing treatment.
Is Matthew Pianko, M.D. currently recruiting for clinical trials?
Yes, Matthew Pianko, M.D. is currently recruiting for 2 clinical trials in Ann Arbor Michigan. If you're interested in participating, you should apply.
Are there any treatments that Matthew Pianko, M.D. has studied deeply?
Yes, Matthew Pianko, M.D. has studied treatments such as Dexamethasone, Bortezomib, Lenalidomide.
What is the best way to schedule an appointment with Matthew Pianko, M.D.?
Apply for one of the trials that Matthew Pianko, M.D. is conducting.
What is the office address of Matthew Pianko, M.D.?
The office of Matthew Pianko, M.D. is located at: University of Michigan, Ann Arbor, Michigan 48109 United States. This is the address for their practice at the University of Michigan.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.